

## Rosmantuzumab

Cat. No.:	HY-P99401
CAS No.:	1684393-04-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors <sup>[1]</sup> .	
In Vivo	Rosmantuzumab (25 mg/kg; i.p., once a week for 4 weeks) significantly protects the animals from developing liver fibrosis <sup>[1]</sup> . Rosmantuzumab (25 mg/kg; i.p., once for two weeks, for total 6 weeks) significantly inhibits skin thickness, collagen deposition, and number of α-SMA positive cells in bleomycin-induced lung fibrosis mouse models <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male C57B1/6J CCl4 liver fibrosis mouse models <sup>[1]</sup>
	Dosage:	25 mg/kg
	Administration:	Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks
	Result:	Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation.

### REFERENCES

[1]. Zhang M, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA